机构:[1]Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, 300384, People's Republic of China.[2]Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Capital Medical University, Beijing, China.首都医科大学附属北京同仁医院首都医科大学附属同仁医院[3]Beijing Institute of Ophthalmology, Beijing, China研究所眼科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院
National Natural Science
Foundation of China (Grant 81570872), Tianjin Research Program
of Application Foundation and Advanced Technology (Grant 15JCYBJC24900),
Science and Technology Project of Tianjin Health Commission
(Grant Numbers MS20025), Open Project of Tianjin Key
Laboratory of Retinal Functions and Diseases (2021tjswmm001),
and Tianjin Key Medical Discipline (Specialty) Construction Project
(TJYXZDXK-037A).
第一作者机构:[1]Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, 300384, People's Republic of China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Xu Fei,Jiang Meixia,Tang Qin,et al.MiR-29a-3p inhibits high-grade transformation and epithelial-mesenchymal transition of lacrimal gland adenoid cystic carcinoma by targeting Quaking[J].MOLECULAR BIOLOGY REPORTS.2023,50(3):2305-2316.doi:10.1007/s11033-022-08150-1.
APA:
Xu Fei,Jiang Meixia,Tang Qin,Lin Jiaqi,Liu Xun...&Lin Tingting.(2023).MiR-29a-3p inhibits high-grade transformation and epithelial-mesenchymal transition of lacrimal gland adenoid cystic carcinoma by targeting Quaking.MOLECULAR BIOLOGY REPORTS,50,(3)
MLA:
Xu Fei,et al."MiR-29a-3p inhibits high-grade transformation and epithelial-mesenchymal transition of lacrimal gland adenoid cystic carcinoma by targeting Quaking".MOLECULAR BIOLOGY REPORTS 50..3(2023):2305-2316